5-Amino-1MQ
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
Search peptides, goals, protocols and references
FEMETRIC PEPTIDE INDEX
Search, filter and compare the current published research records.
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
A copper-binding tripeptide studied in ex vivo human hair follicles and cultured dermal papilla cells.
A modified growth-hormone fragment studied in metabolic and obesity research, with limited supportive clinical efficacy data.
A gastric-derived research peptide studied primarily in preclinical tissue-repair and gastrointestinal models.
An investigational long-acting amylin analogue studied alone and with semaglutide for weight management.
An investigational fixed combination of cagrilintide and semaglutide studied in metabolic and weight-management trials.
A long-acting growth hormone-releasing hormone analogue studied in healthy adults for GH and IGF-1 pharmacodynamics.
A synthetic tetrapeptide studied mainly in cellular and preclinical aging models, with limited independently replicated human evidence.
A naturally occurring copper complex researched in skin remodeling, tissue quality and repair contexts.
A non-standardized commercial blend name that may combine copper, repair or antioxidant components depending on the vendor.
A naturally produced antioxidant researched in oxidative stress, redox balance and pigmentation contexts.
A mitochondrial-derived peptide studied in cellular stress, metabolism and age-associated disease models.
A selective ghrelin-receptor agonist studied as a growth hormone secretagogue, with limited modern human clinical evidence.
An endogenous neuropeptide central to GnRH signaling, studied in reproductive endocrinology and psychosexual research.
A vendor-defined blend name commonly combining repair, inflammatory and cosmetic research peptides.
A three-amino-acid melanocortin fragment studied in intestinal transport and inflammatory models.
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.
An endogenous antimicrobial peptide studied in innate immunity, inflammatory signaling and wound biology.
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
A mitochondrial-derived peptide studied in metabolic signaling, cellular stress and exercise models.
An endogenous coenzyme central to redox chemistry and cellular energy, distinct from its oral precursor compounds.
A peptide hormone with established obstetric uses and research spanning lactation, social processing and sexual function.
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
A melanocortin receptor agonist approved in the U.S. for acquired, generalized HSDD in premenopausal women under defined label conditions.
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.
A synthetic tuftsin-derived peptide studied mainly in Russian-language anxiety, immune and neurobehavioral research.
An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes.
A synthetic peptide developed from an ACTH fragment and studied mainly in Russian-language neurologic and cognitive research.
A GHRH(1-29) analogue formerly approved for pediatric diagnostic and treatment contexts and later discontinued commercially.
A mitochondria-targeted peptide with clinical research across mitochondrial disorders and a U.S. accelerated approval for Barth syndrome.
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
A synthetic N-acetylated fragment associated with thymosin beta-4 research and anti-doping analysis.
A GHRF analogue approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy, with additional research contexts.
A thymic peptide with human clinical research across infectious, immune and oncology contexts; regulatory status varies by country.
An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.